Inhibrx Biosciences is trading 5.01% higher at $84.30, with biotech-sector strength providing the clearest available context; no company-specific catalyst has been linked to the move. - Biotech was reported up 2.01%, with sentiment supported by Moderna’s earnings and raised 2026 outlook. - Inhibrx Biosciences had a scientific presentation scheduled for November 6, but available information does not link it to the share-price change.